A treatment slows a biological age clock in a controlled trial
A clock is only useful to a trial if a treatment can move it, and the first clear case came from the oldest treatment in the field. The CALERIE trial cut the calories of 145 healthy adults by about twelve per cent for two years, against 75 who ate as usual, and in 2023 a Columbia and Duke group read the pace of ageing from their blood, with DunedinPACE, before and after: the restricted group's pace had slowed by two to three per cent, while the clocks that read the level of age (not the pace) did not move. It is a controlled, pre-planned analysis of a treatment on a clock, with the caution that the clock's own validity is the companion leaf's business. The treatment here, eating less, is not a drug; the leaf is about the measurement, and any treatment counts.
What would count
A controlled trial in people, with the clock analysis planned before the data were unblinded, reports that a treatment slowed or reversed a validated clock compared with the control group, in a peer-reviewed report that names the clock. For the clinic rung: a regulator's approval, or a named clinical setting's published routine practice, rests on a clock result from such a trial.
Who settles it: The peer-reviewed trial report with its pre-registered plan; the regulator's approval record, or a named clinical setting's published practice, for the clinic rung.
Where it stands
First human. Reached 9 February 2023, on the record of Waziry and 21 others, 9 February 2023 (doi.org). Next rung within 5 to 20 years.
When it reaches the clinic: the project's estimate
This is the one thing on this page that is a judgment rather than a record. The project's estimate of the year it reaches the clinic is 2037, no earlier than 2030 and no later than 2070; the model draws from that range every run, with the likely year the most probable draw. Set 16 October 2026, a first pass awaiting an outside review.
| Rung | No earlier than | Most likely | No later than | |
|---|---|---|---|---|
| In clinical use | 2030 | 2037 | 2070 | feeds the year at the top |
Why. The clinic rung needs an approval or a published routine practice resting on a clock result, which waits on a regulator accepting a clock (likely around 2040 on that leaf) or on a named clinic adopting clock-guided treatment and publishing it, which the test allows and which could come sooner; the likely year is 2037, the earliest assumes a clinic's practice is published within four years, and the latest allows for the clocks never earning that standing.
Changes to this record
- 17 October 2026, notes: (nothing; text added at the end of the notes) became Added 2026-10-17, from the weekly reading of that date: a 2026-09-07 paper in Nature Biotechnology (zhavoronkov-2026) applied six blood-protein clocks to stored samples from a placebo-controlled phase 2a trial of the lung-scarring drug rentosertib in 42 people, and all six predicted a lower biological age in the treated groups. The authors call the findings exploratory and say the clocks cannot separate slower ageing from an improved lung; the clocks were run on samples already collected, so, like the 2023 CALERIE paper, it was not a clock analysis planned before the data were unblinded, and it does not settle a rung. Statements by Eli Lilly and Novo Nordisk that clocks show people on their weight-loss drugs ageing more slowly (reported by MIT Technology Review on 2026-10-06) are company statements, were not opened, and are not the kind of record the test asks for. No stage or year was changed.. [reading 2026-10-17] Adds the rentosertib clock paper and notes why it does not settle a rung, in line with John's ruling of 2026-10-17 on the CALERIE paper. Source: Zhavoronkov and 12 others, 7 September 2026.
The last readings
- 17 October 2026 Left for the author
Nothing dated in the window, but two older records the leaf does not mention bear on its first-human test. A Nature Biotechnology paper reported by press as published 2026-09-07 applied six proteomic ageing clocks to serum from the placebo-controlled phase IIa trial of rentosertib (Insilico Medicine) in 42 people with idiopathic pulmonary fibrosis and found lower predicted age in the treated arms than in placebo over twelve weeks, with the authors calling it exploratory, which on the press reading makes it a post hoc analysis like the 2023 CALERIE paper. MIT Technology Review reported on 2026-10-06 that Eli Lilly and Novo Nordisk say molecular clock readouts show people on their weight-loss drugs ageing more slowly, which is a company statement and not the peer-reviewed report the settler names. Neither page could be opened from this session. Left for the author, resolved on 17 October 2026: I would add the rentosertib paper (2026-09-07) to the publications log as a record bearing on this leaf's first-human test, with settled_stage false unless its own page shows the clock analysis was planned before unblinding, and would mention in the leaf's notes that company clock readouts (Lilly and Novo Nordisk, reported 2026-10-06) exist but are not the settler's kind of record. The paper is dated before the window and is not named in the leaf, so the entry as written was missing it; whether it changes the leaf's wording, and whether an exploratory analysis in a disease trial counts at all, is the author's ruling. I could not open the paper, so its title, authors, DOI and the pre-specification question are unchecked. To log in the publications log once its page has been read, as the reading's rule asks: unchecked (press coverage: six proteomic ageing clocks applied to the rentosertib phase IIa trial) (Nature Biotechnology (2026), date per press coverage, 2026-09-07; https://insilico.com/news/rnt0709261-rentosertib-proteomic-aging-clocks).source 1, source 2, source 3, source 4
What the story so far says about it
On the record
- 9 February 2023Effect of long-term caloric restriction on DNA methylation measures of biological aging in healthy adults from the CALERIE trial
- 7 September 2026Integration of proteomic aging clocks in a phase 2a clinical trial supports simultaneous geroprotective assessment
Notes
Ruled by John on 2026-10-17, as the verify session proposed: the 2023 CALERIE paper does not settle this leaf's rung, because the paper itself calls its clock analysis a post hoc analysis (the assays were blind to trial arm, but the analysis was not planned before the data were unblinded), and the test asks for one planned in advance. The publication record (waziry-2023) therefore keeps settled_stage false, though it stays the leaf's stage record as written. The leaf exists so that the tree separates three things that get mixed up: a clock that predicts outcomes (the companion leaf), a treatment that moves a clock in a controlled trial (this leaf), and a regulator accepting the clock as proof (the regulatory leaf). The 2019 TRIIM result on the cell-settings branch moved clocks but had no control group, which is why this leaf rests on the 2023 result. Added 2026-10-17, from the weekly reading of that date: a 2026-09-07 paper in Nature Biotechnology (zhavoronkov-2026) applied six blood-protein clocks to stored samples from a placebo-controlled phase 2a trial of the lung-scarring drug rentosertib in 42 people, and all six predicted a lower biological age in the treated groups. The authors call the findings exploratory and say the clocks cannot separate slower ageing from an improved lung; the clocks were run on samples already collected, so, like the 2023 CALERIE paper, it was not a clock analysis planned before the data were unblinded, and it does not settle a rung. Statements by Eli Lilly and Novo Nordisk that clocks show people on their weight-loss drugs ageing more slowly (reported by MIT Technology Review on 2026-10-06) are company statements, were not opened, and are not the kind of record the test asks for. No stage or year was changed.
Not yet verified
These facts in the record were written from memory or from a secondary source and have not yet been checked against the paper, the regulator's record or the registry. Nothing here is presented as settled until it is cleared, by checking it and either deleting the line or correcting the record.
- Company statements that clocks show people on weight-loss drugs ageing more slowly (Eli Lilly and Novo Nordisk, reported by MIT Technology Review on 2026-10-06) were not opened; no peer-reviewed report of them was found.